Sera Prognostics' PreTRM: A Speculative Buy In Women's Health [Seeking Alpha]
Sera Prognostics, Inc. - Class A (SERA)
Company Research
Source: Seeking Alpha
The PreTRM test analyzes specific proteins and gestational age to provide accurate risk assessment for preterm birth. Sera Prognostics specializes in women's health through its flagship product, PreTRM, with an 88% sensitivity for predicting preterm births. Sera's platform includes a biobank and analytical capabilities, allowing for advanced proteomics research and potential expansion into other pregnancy-related conditions. Significant uncertainties and competitive risks exist, yet I believe SERA's potential in the prenatal care market is vast and justifies it as a viable speculative "buy." Sera Prognostics Inc. is a frontrunner specializing in women's health diagnostics with its PreTRM test and innovative platform with extensive biobank and analytical capabilities. They can perform a medical examination, a clinically validated blood test administered between the 18th and 20th weeks of pregnancy, which offers a personalized and accurate risk assessment for preterm birth beyo
Show less
Read more
Impact Snapshot
Event Time:
SERA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SERA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SERA alerts
High impacting Sera Prognostics, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
SERA
News
- Female Health Tech Market Report 2024-2034, Featuring Athena Feminine Technologies, Bloomlife, HeraMED, iSono Health, Minerva Surgical, NUVO, Prelude Fertility, Sera Prognostics, Univfy and TotoHealth [Yahoo! Finance]Yahoo! Finance
- Female Health Tech market is estimated to grow at a CAGR of 9.6% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]Yahoo! Finance
- Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- SERA PROGNOSTICS REPORTS FOURTH QUARTER 2023 FINANCIAL RESULTS [Yahoo! Finance]Yahoo! Finance
SERA
Earnings
- 3/20/24 - In-Line
SERA
Sec Filings
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- SERA's page on the SEC website